Merck KGaA (MRK) Earnings Call Transcript & Summary
August 6, 2020
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and thank you for joining the Merck Investor and Analyst Conference Call covering the second quarter of 2020. Just a quick note that everyone on the line is in listen-only mode for this session. At this point, I'll turn things over to Constantin Fest, our Head of Investor Relations, and he'll guide you through the call. Constantin, please go ahead.
Constantin Fest
executiveMany thanks, Anna. Ladies and gentlemen, a very warm welcome from me. I'm Constantin Fest, and I head up Investor Relations here at Merck. It's a pleasure to be joined today by Stefan Oschmann, our Group CEO, and Marcus Kuhnert, our Group CFO. Over the next few minutes, we'll walk you through the slides in this presentation, and afterwards we'll gladly take any questions you have. With that said, let me hand things straight over to Stefan to get this presentation started. Stefan?
Stefan Oschmann
executiveThank you, Constantin, and a warm welcome to everyone joining our Q2 earnings call. I'd like to begin on slide number five of the presentation, walking through the highlights. On the whole, Q2 came in mixed, which was no surprise, though it landed a bit above what we ourselves had expected. Group sales fell 2.5% organically, and EBITDA pre was down 11.5% against tough comps. On a reported basis, factoring in modest currency headwinds and meaningful first-time consolidation benefits from Versum, sales rose 3.7% while EBITDA pre declined 5.7%. COVID-19 hit us hard, costing roughly -10% on sales and about -20% on EBITDA pre. That was, in fact, a little better than we had anticipated, but more importantly, I'm proud to say that our organization keeps coping well with the challenges throughout this time of crisis. Infection rates among our staff remain low, supply chains are intact, our output is robust, and costs are well under control. On multiple fronts, we keep making significant contributions to the fight against COVID-19. Our assessment of the impacts of COVID-19 has proven to be pretty accurate, and we are encouraged by the visible signs of recovery across important franchises since early June. Given a resilient performance in the first half, we are slightly raising our EBITDA pre guidance for the full year.
Stefan Oschmann
executiveOur updated outlook now calls for net sales of between EUR 16.9 billion and EUR 17.7 billion, EBITDA pre ranging from EUR 4.45 billion to EUR 4.85 billion, and EPS pre between EUR 5.6 and EUR 6.25. We'll share more on the assumptions behind these figures a bit later, but for now let's move directly to slide six, where you'll find a Q2 overview broken out by business sector. As the slide shows, Life Science delivered another solid performance, with organic sales growth coming in even a touch above Q1, though organic declines in Healthcare and Performance Materials more than offset that. Currency effects created a slight overall headwind, while a substantial lift from portfolio effects helped push group sales to EUR 4.12 billion, a rise of 3.7%. Turning back to Healthcare, note that the organic sales decline stemmed almost entirely from weaker demand in fertility as COVID-19 related clinic closures took their toll. Meanwhile, the expected drop in Rebif was roughly balanced out by muted growth across the rest of the portfolio, which in turn was also largely attributable to COVID-19 related effects. In Life Science, very strong organic growth of +20% in process solutions was offset by adverse demand effects in applied and research solutions. The latter mainly reflected lockdown conditions in Europe and North America, which weighed heavily on the academic customer segment in particular.
Stefan Oschmann
executiveWithin Performance Materials, robust organic expansion in semiconductor solutions picked up further, reaching the low teens, though organic drops in display and surface solutions outweighed this by more than the gain, as COVID-19 left its marks. Turning to earnings, group EBITDA pre reached EUR 1.07 billion, equivalent to a 26.1% margin, a decline of 260 basis points. The main reason is substantially higher non-recurring income in Healthcare during the prior year. Once those differences are adjusted for, the margin on an organic basis would have risen by over 100 basis points, since fixed cost underabsorption from reduced sales due to the COVID-19 effect was more than compensated by continued cost discipline and lower travel spending. Moving to slide seven for some remarks about regional sales performance in Q2. Organic sales fell within the low to mid single digits across each of our three primary regions: APAC, Europe, and North America. In every one of those regions, organic growth in Life Science was outweighed by organic decreases in Healthcare and Performance Materials. Notable points include double-digit organic growth for process solutions in all major regions and double-digit organic growth for semiconductor solutions in APAC. Negative effects tied to COVID-19 were experienced in every region, albeit to varying degrees, generally depending on the business mix and how exposed each was to lockdowns.
Stefan Oschmann
executiveSo with that, I'll pass things over to Marcus, and he's going to give you more detail on how the finances came out and what the big developments were in Q2. Marcus, over to you.
Marcus Kuhnert
executiveThanks, Stefan, and a warm welcome to everyone also from my side. I'm now on slide nine with an overview of our key figures for Q2. Stefan has already guided you through the most important drivers for sales and EBITDA pre. Let me add a bit more color on the topic of non-recurring income in healthcare. As you know, Q2 last year included around EUR 190 million in total, comprising around EUR 75 million from the Peg-Pal milestone, around EUR 50 million for deferred income from Pfizer, around EUR 35 million for U.S. FDA approval of BAVENCIO and RCC, and around EUR 30 million of deferred income from GSK. Q2 this year included around EUR 25 million in total, comprising around EUR 20 million of deferred income from GSK and around EUR 5 million from active portfolio management. That said, we confirm our full year guidance for up to a mid-double digit million EUR amount from active portfolio management. We booked around EUR 5 million in H1 and expect, so that, of course, without GSK, and expect most of the remaining amount in the third quarter. Regarding the deferred income from GSK, we update our full year guidance to around EUR 100 million.
Marcus Kuhnert
executiveWe recorded roughly EUR 50 million in H1, and we expect the rest to be divided evenly between Q3 and Q4. As always with the standard disclaimer, keep in mind that this figure may change, based on how costs for the program evolve and whether development milestones are reached. I'll also make a brief remark on EPS pre, which fell more quickly than EBITDA pre, chiefly because of a larger negative financial result. And lastly, the reduced operating cash flow stems mostly from the EUR 300 million upfront payment received from GSK last year, along with higher working capital this year. Let's now turn to our reported figures on slide 10. Although EBITDA pre fell EUR 65 million in the quarter, reported EBIT dropped by EUR 127 million. In fact, we saw a net positive effect of approximately EUR 50 million, coming from lower amortization of intangibles and lower adjustments on one side, and higher regular D&A on the other. However, this was more than offset by impairments of around about EUR 100 million in Performance Materials — sorry, EUR 110 million in Performance Materials, mostly tied to intellectual property acquired through AZ Electronic Materials in 2014. The financial result came in lower, chiefly because of higher LTIP provisions and higher interest expenses related to the Versum financing.
Marcus Kuhnert
executiveI'd also like to point out that we've nudged down our guidance for the full-year interest result somewhat, to a range of between EUR 280 million and -EUR 310 million, largely driven by interest expense tied to tax provisions. That's likewise the primary factor behind our EPS pre-guidance staying as it was, even though our EBITDA pre-guidance has been raised. The effective tax rate landed inside the 24%-26% guided range, and as a result, reported EPS was EUR 0.67 versus EUR 1.08 in Q2 of last year. That said, let's turn to reviewing our three business sectors, beginning with healthcare on slide number 11. As one would expect, healthcare delivered a soft quarter on the whole, with sales declining 7.4% organically, since meaningful but slower growth of 34.1% in new products was more than outweighed by a 9.6% drop in the core business. The negative effect of COVID-19 was substantial, at close to EUR 300 million — put another way, absent that, we'd have posted yet another quarter of very strong growth, with organic growth of close to 10%. As anticipated, fertility took the biggest hit in absolute terms, with our N&I franchise, and MAVENCLAD in particular, next in line. We likewise experienced a notable effect on general medicine and endocrinology, while oncology saw only limited impact.
Marcus Kuhnert
executiveThe positive side is that since early June we see clear and wide-ranging indications of a rebound, and those reflect the basic relevance of what is in our portfolio. As an illustration, June sales of MAVENCLAD had nearly returned to where they stood before the crisis and continue to climb. Fertility is steadily recovering now that clinics are reopening. General medicine and endocrinology are getting back to normal following some de-stocking effects caused by Q1 pull-ins. Turning to earnings, Healthcare EBITDA pre fell 25.9% organically during the second quarter, though this stemmed mainly from substantial differences in non-recurring income compared with last year, as we explained to you earlier. In fact, the under-absorption of fixed costs amid lower sales caused by the COVID-19 effect was more than compensated for by a substantial cutback in in-person face-to-face activities and by our continued rigorous cost discipline. Given how resilient our H1 performance has been, we are modestly lifting our organic EBITDA pre-guidance for Healthcare, and now anticipate roughly stable development in 2020. Please bear in mind that this comes despite the third round of volume-based procurement in China that was announced recently, which includes metformin as expected and will probably be implemented at some point in the fourth quarter. On the pipeline side, the obvious standout of the quarter was the U.S. FDA approval of BAVENCIO in first-line bladder. I can share that early feedback from the launch in this potentially significant indication has been very encouraging.
Marcus Kuhnert
executiveMoving on, slide 12 gives us the Life Science review. Life Science delivered another strong quarter, posting organic sales growth of 6.3%, which is actually a touch above what we saw in Q1 even with the COVID-19 difficulties continuing. As a matter of fact, COVID-19's net negative effect landed in the mid double-digit million EUR, so somewhat larger than in Q1. Regionally, matching how lockdowns rolled out, Asia Pacific sped up into double-digit organic growth, Europe posted high single-digit growth, and North America eased to low double-digit growth. On customer segments, reflecting how lockdowns hit lab activity, demand kept moving away from academia toward pharma and biotech plus diagnostics. Indeed, academia stood out as the sole customer segment shrinking, though here too we've seen encouraging recovery signals in June. Looking at the product portfolio, process solutions continues to shine, with organic growth climbing to a very strong 19.8%, driven mainly by downstream and single use. COVID-19-related demand from therapy and vaccine developers helped sales on a net basis and helped the order book even more.
Marcus Kuhnert
executiveApplied solutions posted no change once more, and COVID-19's impact was negative on balance throughout every business line. Still, lab water returned to growth during Q2, and applied solutions overall experienced a robust June rebound. Research solutions lagged behind in Q2, with organic sales falling 7.1%. COVID-19's net effects were unfavorable, with every business declining — not unexpected, since research solutions carries the greatest exposure to academia. As with Applied, June showed considerably better momentum. Turning to earnings, EBITDA pre reached a solid EUR 569 million, driven by organic growth of 9.7% and a margin that rose to 31.5%, largely thanks to operating leverage. Our full year guidance for strong organic EBITDA pre-growth in Life Science is confirmed, and our confidence in it keeps building. Moving now to slide 13, let's review Performance Materials, which delivered a mixed quarter overall. Reported sales growth was robust at 38.1%, reflecting modest FX tailwinds plus a sizable portfolio effect from Versum. On an organic basis, sales fell 13.7%, chiefly because of substantial COVID-19 impact. We put that effect in the mid to high double-digit million euros, against only a small unfavorable effect in Q1. Much like Life Science, the picture differs considerably across business units.
Marcus Kuhnert
executiveSemiconductor solutions, which accounts for nearly 60% of Performance Materials sales, posted another robust quarter, with organic growth of 12.1% that outpaced the market. Although COVID-19 had a minor negative impact, this result exceeds Q1 and supports our belief that the cyclical trough is now behind us. Please also note that legacy Versum's growth was in line with this, and integration is still progressing well, with synergies materializing somewhat sooner than anticipated — that is, we now anticipate at least EUR 25 million in cost synergies for this year, versus roughly EUR 20 million expected before. Display solutions sales fell -20.8% organically, against still-high comparables in liquid crystals and a significant COVID-19 effect. As we already indicated to you in May, COVID-19 is modestly adding pressure to the negative underlying trend in liquid crystals, while the negative impacts in OLED look temporary. In surface solutions, organic sales dropped 29.6%, mirroring the heaviest COVID-19 blow within Performance Materials owing to its exposure to automotive and cosmetics end markets. Broadly, although Performance Materials is likely to keep facing adverse COVID-19 effects in Q3 and 4, we observe indications of moderation relative to Q2. Turning to earnings, reported EBITDA pre rose 25.2%, since the organic decrease was more than compensated for by the Versum portfolio effect and modest currency tailwinds.
Marcus Kuhnert
executiveI'd also like to point out that expenses are still firmly in check, thanks to solid execution of our Bright Future transformation program along with measures addressing COVID-19. As a matter of fact, on a like-for-like basis, both marketing and selling as well as R&D were down in the second quarter. Last but not least, for Performance Materials we are nudging up our full year EBITDA pre-guidance a bit. Stefan will share further details on that later. Turning to slide 14, I'll offer a few comments about our balance sheet. As the chart shows, there's actually very little difference versus year-end 2019. Cash and cash equivalents are still roughly EUR 750 million higher, consistent with the end of March and mirroring our cautious stance on securing liquidity through this crisis period. As a reminder, factoring in the EUR 2 billion syndicated bank loan, we hold a comfortable liquidity buffer above EUR 3 billion. And our equity ratio is still over 40%. Debt to EBITDA pre improved a touch, from 2.8 at the close of December to 2.7 at the close of June. Let's now look more closely at second quarter cash flow on slide 15. As you can see, operating cash flow reached EUR 502 million, versus EUR 743 million in Q2 of last year.
Marcus Kuhnert
executiveThe primary drivers involve a variance in movements across other assets and liabilities, chiefly reflecting last year's GSK upfront payment of EUR 300 million along with larger working capital outflows in the current year, mostly because of the Versum consolidation and COVID-19 effects. Accounts receivable increased only modestly, but inventories showed a larger impact, since maintaining supply security ranked as a major priority for us during the second quarter. CapEx rose as planned, whereas investing cash flow a year ago was largely shaped by temporary investments of proceeds from the consumer health divestment. In a similar vein, financing cash flow is back at a more normal level, given that last year carried significant effects from bond issuance tied to financing the Versum acquisition. With that, I'll return the floor to Stefan for the outlook.
Stefan Oschmann
executiveThanks, Marcus. Moving to slide 17 now. To sum up, Q2 was solid even with COVID-19 causing considerable negative effects. Those effects matched the assumptions we shared with you in May. As this slide shows, our revised assumptions about how COVID-19 develops as a pandemic are largely unchanged. We continue to anticipate an impact in every region and expect the recovery to move forward during the second half. We also continue to assume certain countries will have difficulty containing the virus, which means healthcare systems will stay under strain. Whereas previously we assumed no major resurgences, we are refining that statement and now assume there will be additional flares, though these will not set off new widespread lockdowns. We don't assume this is the sole possible scenario or the absolute truth, but we want transparency about what our planning is based on. Moving to slide 18, which offers some additional color on how the COVID-19 pandemic is affecting our business. Normally we don't report monthly sales trends, but we believe exceptional times call for exceptional disclosure. This illustration should give you a clearer understanding of the dynamics during the current crisis and of our expectation for a recovery in the second half of the year, subject, of course, to the assumptions we discussed a minute ago.
Stefan Oschmann
executiveSo, as you can see, the group's organic sales growth has tracked very closely with how lockdowns unfolded — especially mandatory workplace closures. In fact, looking at the year to date, April and May were the only months that posted negative organic sales growth, whereas June delivered a striking swing of +18 percentage points, reaching +7% organic. Obviously, certain negative effects will probably persist longer than others, yet the bulk of our business is extremely resilient and mostly unaffected by what one might term the new normal in the midst of this ongoing pandemic. On top of that, we contribute meaningfully to combating COVID-19 via our healthcare and Life Science business sectors, and through Performance Materials we serve a vital role in addressing the fast-rising demands of digitalization. Combined with agile and active management, this puts us in a position to do far better than many others, and we stay confident that we'll come out of this crisis even stronger. Before I move on to the financial guidance, allow me to expand on that thought a little more using Life Science as an example. Let's turn to slide 19. On the left-hand side here, you'll see what we call the COVID-19 heat map — a three by four matrix with two dimensions, specifically our Life Science business units and the customer segments we operate in.
Stefan Oschmann
executiveEvery one of the 12 fields shows how sensitive a business is to COVID-19, where plus signs stand for gross upsides and minus signs stand for gross downsides in 2020. Over on the right-hand side of the slide, we present how monthly sales for the Life Science business sector developed by customer segment during the first half of 2020 versus the first half of 2019. So what are the main takeaways from this slide? As with many others, we observe a combination of different factors. First, lockdown conditions have brought temporarily lower demand in various parts of our portfolio, hitting research and applied solutions mainly, and chiefly among customers working in academia. Yet demand is fundamentally unchanged, and since June we have seen clear signals of recovery. Second, there is substantial surge demand in high-value parts of our portfolio, coming from customers active in COVID-19 diagnostics, vaccines, and therapies. For instance, our process solutions order book is up by more than 40% year-to-date, and necessary capacity expansions to meet this demand are progressing well. In summary, Life Science is highly resilient during this crisis, and ups and downsides should roughly offset each other in the current year.
Stefan Oschmann
executiveAnd at the same time — this is a key point, I think — the negatives began easing in June, and we're in a strong position to take advantage of some of the enduring positives over the medium term. So with that said, let me turn to guidance. Slide 20 gives you an overview of the revised assumptions we've made about how COVID-19 will affect us financially. Broadly speaking, our underlying view of the situation is largely unchanged, though with better visibility combined with solid execution, we've shifted a bit more optimistic. Specifically, we now anticipate COVID-19 will hurt full-year group sales by up to mid-single digit percentages, versus mid-single digits previously, while we still expect a drop-through of 50%-60% on EBITDA pre alongside contingency measures already in place. As for phasing, the recovery that got underway in June should carry on through Q3 and Q4. Turning to our three business sectors, we continue to expect Healthcare to bear the largest absolute impact, Life Science the smallest, and Performance Materials somewhere in between. Looking further at healthcare, fertility will be hit considerably, though the worst appears to be behind us as clinics keep reopening, while we foresee only modest effects on the remaining franchises in the second half, and MAVENCLAD should regain momentum, as the encouraging June trends suggest.
Stefan Oschmann
executiveWhen it comes to life science, as I explained earlier, we anticipate that positive net effects in process solutions will be offset by negative net effects in research and applied; nevertheless, those latter two should keep recovering in line with what June showed us. Finally, in Performance Materials for display and surface solution, we are seeing indications that COVID-19 pressure will ease somewhat in Q3 and Q4 versus Q2. Even though market forecasts are giving mixed signals, we stay confident about continued strong growth in semiconductor solutions, drawing on thorough channel checks and routine talks with our customers. Slide 21 gives you a quick recap of the main earnings drivers for 2020. There is no change from the version we shared in May, apart from refining the wording on anticipated growth in semiconductor solutions to match the bullish remarks I just made, and a possible VBP effect in China near year-end, which our guidance already fully incorporates. Let us move directly to the group guidance on slide 22. To sum up, we narrowed the corridor for group net sales guidance by EUR 200 million, lifted the bottom end of the EBITDA pre-range by EUR 100 million, and tightened the EPS pre-corridor by EUR 0.20.
Stefan Oschmann
executivePut differently, for 2020 we now anticipate group net sales of between EUR 16.9 billion and EUR 17.7 billion, EBITDA pre of between EUR 4.45 billion and EUR 4.85 billion, and EPS pre of between EUR 5.6 and EUR 6.25. On an organic basis, we now forecast slight to moderate growth in both sales and EBITDA pre, whereas before this guidance applied only to sales, while EBITDA pre was expected to be about stable. The portfolio effects we anticipate from Versum are confirmed at a mid-single-digit percentage tailwind for net sales and EBITDA pre alike, though our confidence has grown, as I will explain shortly. On exchange, we now assume somewhat larger headwinds for both sales and EBITDA pre. To be specific, we foresee an adverse impact of 0% to -2% on sales and -2% to -4% on EBITDA pre, versus +1% to -2% and 0% to -3% previously, respectively. Lastly, a few remarks on the guidance for our business sectors found on Slide 23. Although it stays qualitative given the ongoing uncertainty caused by COVID-19, you will see that we have turned more positive on organic sales and EBITDA pre-development in Healthcare, and likewise on organic EBITDA pre-development in Performance Materials and the portfolio effects from Versum.
Stefan Oschmann
executiveBut I should add that when it comes to Performance Materials, you should view our organic sales guidance as more and more conservative, and our confidence has grown when it comes to strong organic sales and EBITDA pre-growth for Life Science. With that said, let's move on to your questions.
Constantin Fest
executiveAnna, could we take the first question, please? Thank you very much.
Operator
operatorThank you. We're moving into the question-and-answer part now. Should you wish to pose something to our presenters, press star one on your phone's keypad at this point to join the line. After we announce your name, you'll be able to ask. If your question gets answered prior to when you're called on, press star two and it will be withdrawn. Anyone on speakerphone today should pick up the handset before keying in a selection. Our opening question comes from Matthew Weston at Credit Suisse. The line is yours.
Matthew Weston
analystThank you. I have two questions, please. The first is about Life Science and the remark concerning the 40% rise in order book demand. That has drawn considerable attention this morning, so I would just like you to place it in context, please. My assumption is that inside your revenue there are a whole series of repeat customers whom you know are there with a very stable outlook while they continue to make drugs for many years. There are growth drivers as new customers come on. If you can put that 40% in context as to how much growth it would support within the existing total business portfolio, I think that would be extremely useful. Secondly, on Glucophage and VBP. Thank you for all the information. Can I just try and understand, in your annual report, you report the amount of earnings you pay away to your partner, Bristol-Myers Squibb, for Glucophage in China. Can you help us understand what proportion of the profitability of the joint venture that represents? Is it essentially a 50/50 profit split, or do you pay them a royalty? If you could frame at least somehow the maximum earnings downside from Glucophage VBP, I think people would find that extremely helpful.
Matthew Weston
analystThanks.
Stefan Oschmann
executiveMatthew, Stefan here. Could you clear up that VBP question for us? We’re not sure which joint venture you mean.
Matthew Weston
analystRegarding Glucophage in China, from what I understand, you pay Bristol-Myers Squibb a 16% royalty. That's what I believe it amounts to for Glucophage. To the best of my knowledge, that's disclosed in the annual report. Perhaps that arrangement has now concluded, but historically, you did pay it until the end of last year. So it would help us understand how profitable Glucophage is if you were making partner payaways, and we all assume that China is traditionally a market with lower margins.
Stefan Oschmann
executiveYes. Let me begin with the Life Science question. Yes, we have heard that a few times, and that figure was held up against numbers published by competitors and was regarded as very favorable. There is no way to scientifically predict how much of that is precisely surge demand versus repeat demand. Let me attempt to provide some clarity. On the whole, we estimate that the growth upside from this surge demand in Process Solutions and also in the Diagnostics area sits at a low to mid 3-digit level. That is the growth impact. We also have certain negatives, as you mentioned. That concerns the effect on 2020. We should bear in mind that this surge demand we are observing will only convert into sales. A portion of it will only convert into sales past the current year. Given this very strong order intake in Process Solutions over, say, as much as 40% year to date, one could assume that approximately 50% of that stems from COVID-19 related surge demand. Also, Matthew, I was discussing capacity expansion. As we noted on our Q1 earnings call, we are capacity constrained in certain areas of our portfolio where demand has surged mostly because of COVID-19.
Stefan Oschmann
executiveA lot of this really centers on certain downstream offerings and single-use products within process solutions. Together with our customers, we're putting in a great deal of effort to ease these constraints. We've set out clear allocation principles, and we're also collaborating closely with customers to determine what they require and precisely when they require it. Capacity is already on the rise. Through creative shift and staffing models, we're optimizing output from the infrastructure that exists today. Our hiring plans have been sped up, and we're adding physical capacity at 2 of our plants, which ought to be available early next year. We're watching the situation carefully and stand ready to adjust our initiatives. We have strong confidence that capacity will be sufficient over the medium term. Marcus will take the question oriented toward VBP BMS Glucophage.
Marcus Kuhnert
executiveMatthew Weston, first I’d like to use this chance to offer a few broad comments about how VBP could affect our figures in 2020 and, for that matter, later on as well. To begin with, as you’re likely aware, the bidding will happen on August 20. My sense is that we’ll learn the result a couple of days afterward. Based on what we saw in the second round of VBP, our experience indicates that it then takes — I’d say, from the moment the initial list came out — roughly three months before implementation begins in a way that starts producing effects on companies and on their P&Ls. So we anticipate a point, say, early in the first quarter when we could see the first possible effects on our P&L. Right now, we have actually opted for the more cautious approach. That is, our guidance currently includes the full quarterly impact of the VBP outcome in our P&L. Frankly, we also have some scenarios internally, because it’s obviously still unclear what the specific outcome will be. We do know a few guardrails.
Marcus Kuhnert
executiveTo give you an example, we already know that as many as 8 winners will be selected. We know those 8 winners will receive exclusive access to roughly 80% of the hospital market, and we know the hospital market accounts for approximately 70% overall. Now, when we consider the looming P&L effect, it's important to remember that China's metformin market is expected to expand by over 10% each year across the next 2 years or so. There remains a meaningful non-hospital market segment, which won't be affected by a gradient price cut. And eventually, we wouldn't have 8 winners but fewer, with the corresponding consequences for the numbers. Turning this also into some of the questions we received this morning, which I'd like to mention here as well. Naturally, we believe this will have an impact on China beyond 2020 too. However, looking at the period through 2022, we hold to our belief and our guidance that the base business will keep growing. China will also keep delivering positive sales growth through 2022. For 2021, we'd say as of today that we will be at least stable. On profitability, actually, we don't disclose profitability or margins at a country level.
Marcus Kuhnert
executiveYou're right that we do pay license fees in China for BMS. So because of that, profitability there runs a bit below what we see in other parts of the world. That said, Glucophage overall remains very profitable, so at this point we don't anticipate a significant effect from it.
Matthew Weston
analystI really appreciate it, thank you so much.
Operator
operatorThanks. We'll take the next question from Peter Verdult at Citi. Go ahead, please.
Peter Verdult
analystThank you. This is Peter Verdult from Citi. Marcus, prior to his recent departure, Udit was sending messages saying that 2020 could be the final year of margin expansion at Life Science, particularly in light of the investments being made in Asia, viral vectors and gene editing. So, considering the performance delivered in Q2 despite significant headwinds, what you're saying about the outlook for process solutions, the order book and the anticipated recovery of applied and research, would it be reasonable to conclude that this margin outlook may be too conservative given what you're observing? That's question number 1. Number 2, for either Stefan or Marcus. I understand you won't comment on bintrafusp data as such, but a simple yes or no would be enough here. Has the internal look — yet to happen, which we know is coming this year — taken place? Just yes or no, has that internal look happened? If I may, Stefan, just fit one more in. Your IL-17 A/F nanobody in psoriasis — a competitor created a lot of excitement earlier this year with their phase III data. You have a sizable phase IIb study coming up. You never mention it. Is that simply because you've out-licensed it to Avillion, or does it reflect how enthusiastic you are about the asset?
Peter Verdult
analystThanks.
Stefan Oschmann
executiveYes, Peter, perhaps I can take the margin expansion question for Life Science. If my memory serves me, that statement was actually mine, and I said it during the previous quarterly earnings call. What I said was that, as an investor, I would want the business to balance delivering margin with investing in the future, and that no one should assume margin expansion will keep going indefinitely. That remark got picked up by some people. I considered it fairly benign, that comment. As you can see, in Q2 we are seeing additional margin expansion, and at present we see that the high-value segments of Life Science in particular are growing. At the same time, there are exciting novel areas. On the whole, R&D expense at Life Science tool companies is fairly low, and innovation comes about through bolt-on acquisitions. Innovation also comes about through licensing. There is plenty of opportunity in the novel modalities in gene therapy and cell therapy and mRNA, et cetera. You should expect us to strike this balance appropriately, but we have a track record of margin expansion. We are very proud of that. We are also the profitability leader in the industry. We grow above the market, and we do not expect that to change.
Peter Verdult
analystRight there.
Stefan Oschmann
executiveOn bintrafusp, I can give you a very straightforward answer. We can’t discuss any particular interim analysis, because doing so would jeopardize the integrity of our clinical trials. And while we’re unable to say how many of those analyses there are, or how often they occur, in connection with the lung cancer program, what we can tell you is that there are multiple analyses and that they are event-driven. As of the Q2 earnings, the 037 study is active and enrolling patients, and we’ll keep working with the IDMC to monitor how the trial is progressing. You asked about the IL-17A/F nanobody. If I remember correctly, I believe we announced in 2017 that Merck had reached an agreement with a subsidiary of Avillion to develop the IL-17 nanobody, and its code is M1095. Under that cooperation, Avillion will be responsible for developing this asset from phase II through phase III. As of now, however, we have not commented on any phase III timing plans.
Peter Verdult
analystAppreciate it.
Operator
operatorThanks. We'll take the next question from Sachin Jain at Bank of America. Your line's open, so go right ahead.
Sachin Jain
analystApologies — I was muted. Sorry about that. This is Sachin Jain from Bank of America, and I have just two questions. The first follows up on Life Science growth. You've mentioned a 40% order book, and that 50% of it comes from COVID surge demand — so how should we think about market growth, and about your growth relative to it, for 2021, versus what you said earlier about the market growing at 5%-6%? I'd like to know whether you're willing to put more specific numbers on that. Second, in your R&D deck you mention a TGF-beta study that will start in combination with TIGIT. I haven't heard you discuss TIGIT previously, so I was hoping you could give us some perspective on that asset, on when phase I monotherapy data would come, and on what makes the combination with TGF exciting to you. Thank you.
Stefan Oschmann
executiveYes, Sachin. And regarding growth in the Life Science market, your summary of our assumptions was accurate. We are monitoring that situation very closely. Our intention is to discuss our assumptions about future market growth in detail at our Capital Markets Day. At the moment, conditions are so fluid and so volatile. We feel it is a bit early to finally update those assumptions. We believe that by the time our Capital Markets Day arrives, we can give you more granularity. As for the TIGIT trial, that is a first-in-human study involving 35 patients. Since the start of the alliance, we have communicated that we intend to initiate combo studies of bintrafusp alfa with other assets in our portfolio and GSK's. M6223, if my memory serves me, is a mAb compound discovered in our own labs, and this marks the first time we will publish data on M6223. The primary completion date, I believe, falls in the second half of 2022, around September 2022.
Sachin Jain
analystThanks.
Operator
operatorThanks. Our following question is from Morgan Stanley's James Quigley. You can proceed.
James Quigley
analystThanks for taking my questions. James Quigley here from Morgan Stanley. First question is about MAVENCLAD. Could you share some sense of how re-engagement with physicians and doctors has been progressing now that the lockdowns have been lifted? The June data look quite encouraging, but given case spikes in various parts of the U.S., is there any risk physicians might hold off on MAVENCLAD because of the earlier perception you flagged on the Q1 call regarding higher COVID-19 and infections? That's question number one. Question number two, on BAVENCIO and bladder. How are you thinking about market dynamics in the first-line maintenance setting? What marketing message will you use to try to persuade physicians to choose the maintenance approach rather than the PD-1 chemo combination? Have you noticed any biomarkers or any characteristics among patients who may respond longer or deeper with maintenance compared with other patients? Thank you.
Stefan Oschmann
executiveYes, thanks. In fact, our outlook on MAVENCLAD's development is more positive now than it was when we last spoke with you in May. Prescription trends are picking up momentum. On page 23 — sorry, 33 — you'll find some pertinent figures regarding market share and so forth. Based on three factors, we believe the macro backdrop supports a MAVENCLAD recovery. Healthcare practitioners harbor worries about infection risks and vaccine readiness. Real-life data has been published by some of our competitors. Real-life data has also been published by us. In this regard, we consider our information to be quite pertinent. Especially when compared with continuous immunosuppressants, vaccination readiness matters a great deal. Second, we are observing a favorable guideline shift for MAVENCLAD in the U.K., Italy, Germany, and so on. Third, for obvious reasons, the dynamic market was hit hard by COVID. MAVENCLAD held a steady market share, or if you check the chart on page 33, we observe a positive trend. At the pandemic's peak, we had no sales reps in the field; they have been returning since early June. For years, we had placed considerable emphasis on digital outreach to customers, not just in healthcare but in our other businesses as well.
Stefan Oschmann
executiveTake fertility, for example—that's another area where we're really feeling pressure. Our view is that we're performing far better than competitors in these segments, since we entered this period more prepared for a crisis than a lot of others and could therefore emerge from it in a stronger position. Broadly speaking, whether you can get into a physician's office varies by state and by digital engagement. We're quite pleased with the digital access available to us—these are digital sales calls, but also a wealth of digital roundtables, digital congresses, peer-to-peer exercises, and so forth. We monitor this closely, and what I hear from the various country organizations and franchises leaves me very encouraged. You raised a question about BAVENCIO and the feedback on the launch. As you may remember, BAVENCIO received U.S. approval on June 30th, so we're at a very early stage—just one month into the launch. Clearly our standing has been reinforced by the failures of several combo studies, most recently KEYNOTE-361. We regard that as a very encouraging development. And of course, once again, we're launching in the midst of a pandemic. As I said a moment ago, we began adapting our marketing approach quite a while back, and we're pursuing a digital, hybrid strategy—digital plus face-to-face wherever circumstances allow, depending on the situation.
Stefan Oschmann
executiveLately, our regimen has been added to both the NCCN and ESMO guidelines as a preferred option, and in our view that clearly shows how transformative the UC data are. From the field, we're seeing strongly positive early signals regarding how the data have been received and the willingness to adopt them in practice. When we discuss items such as market share, obviously that would be premature, but I'd anticipate you'll pose this question to us at the R&D update call. There will be the capital markets event, and then later this year, toward the end of September, we're holding a separate R&D update call. We should also keep in mind that we anticipate regulatory feedback in Europe as well as Japan during the first half of 2021, and that would set off milestones.
James Quigley
analystThat’s great. Thanks very much.
Operator
operatorThanks. We’ll take the next question from Richard Vosser at JPMorgan. Go ahead.
Richard Vosser
analystHello, and thank you for taking my question. First, returning to the Life Science order book, could you give us a sense of how it splits between consumables and the more substantial equipment, and how you expect that to flow through to sales in terms of timing of realization? My thinking is that consumables may convert much faster while equipment takes longer. Just some thoughts on that. Second, regarding MAVENCLAD, thanks for the update, but could you give us an idea of the split in Q2 as well, please? Third, coming back to Life Science, on the academic lab opening, perhaps you could provide a bit more color on how you see the pace of those labs opening over the remainder of the year and what you've seen so far. Thanks very much.
Stefan Oschmann
executiveRegarding the order book, Richard, there isn’t really a clear-cut line separating equipment from consumables. The demand spike is largely driven by single use and by filters. That does count as equipment, yet in a sense it is consumable equipment, since single use is disposable and filters last only a limited time. If you’re asking whether that will lead to fresh orders, we assume it will. I hope that addresses your question.
Richard Vosser
analystRight.
Stefan Oschmann
executiveRegarding the other Life Science-related question, take a quick look back at slide 19, which lays out monthly sales development for each customer cluster. In the lower left-hand section, academia, it essentially demonstrates that we experienced somewhat of a hit in March, a significant hit during April and May, and then June has returned to previous trends. I think it's reasonable to assume this pattern will hold. Naturally, we can't predict it with 100% certainty, but that is our assumption. Whatever was lost in April and May is lost, yet we're back on the previous track. That has an impact on the second quarter and an impact on the full year, but it doesn't alter the long-term trajectory of the business. Marcus, did you want to add something?
Marcus Kuhnert
executiveYes. Let me quickly address your second question, Richard. You wanted the regional split for MAVENCLAD in Q2, and you might recall what I mentioned on the previous quarterly call. Not much has shifted there. The reason is straightforward: areas outside the U.S. experienced a sharper decline in the second quarter, particularly between March and April, followed by a considerably stronger rebound in June, whereas the U.S. started from a lower base and did not see as steep a fall during the second quarter.
Stefan Oschmann
executiveRegarding your question about MAVENCLAD, during the call we held recently, we mentioned that the division between the U.S. and Europe stands at roughly 40% and 60%, and that the U.S. share has been climbing a bit.
Marcus Kuhnert
executiveYeah, both are still the same.
Stefan Oschmann
executiveYes, pretty much the same. That's the level of detail we'd be ready to share.
Richard Vosser
analystMuch appreciated.
Operator
operatorThanks. We’ll take the next question from Michael Leuchten at UBS. Go ahead.
Michael Leuchten
analystThank you. This is Michael Leuchten from UBS. I have two questions for Marcus, if I may. First, would you mind clarifying what you said about deferred income? My understanding is you mentioned it has now reached triple digits, whereas I think earlier you described it as triple digits. What exactly is behind that shift? Second, regarding your guidance, which milestones are factored into the healthcare guidance for this year? In the past, I believe milestones were excluded from your guidance. Looking at the remainder of the year, is it still the case that no milestones received through today are included, or are some milestones now in there? Thank you.
Marcus Kuhnert
executiveI'll take your second question first. Yes, we haven't put any milestones into our guidance, though we did have some, let's say, non-recurring income. From memory, a mid-double-digit million euro amount. About half of that was booked through the end of June, mostly from the GSK deferred income. We expect, let's say, another eventual amount of up to mid-double-digit million euro in the second half of the year and eventually in the third quarter. On the deferred income recognition for bisoprolol, a reduction to EUR 100 million. As for our R&D efforts, you've probably noticed that in recent weeks we've posted several new bisoprolol studies on ClinicalTrials.gov, including triple negative breast cancer and also bladder, just to name a few. Keep in mind this is an extensive program that we keep driving forward and evolving. We try to be as transparent as we can, and given this transparency effort, we've also tried to guide you as much as possible, but the realization is not linear. We've always stressed that this amount can vary depending on the cost evolution of the program and on reaching development milestones. That's exactly what you're seeing now, with the quarter showing some variation.
Michael Leuchten
analystAppreciate it.
Operator
operatorThanks. Our following question is from KC Akitala at Goldman Sachs. You have the floor.
KC Akitala
analystHi, everyone, and thanks for taking my questions. I have two, please. On process solutions, could I ask about the opportunity stemming from vaccine development? Obviously, multiple approaches are underway to develop a vaccine. Would you say you benefit more if a vaccine based on one particular technology succeeds rather than the others? It would be great if you could frame that opportunity for us, please. On the second one, about Glucophage, thanks for the detailed info. Very helpful. Can you give us a rough idea of your current volume share for Glucophage in China's metformin market, in the hospital channel? How does that compare with your volume share for Concor in the bisoprolol market? Thank you.
Stefan Oschmann
executiveRegarding your question about process solutions, it's hard to give a simple answer, since as we mentioned earlier, we're backing 45 vaccine projects. Let's see. Those vaccine projects vary widely. Some are traditional vaccines. Some are viral vector-based vaccines, DNA-based vaccines. Others are mRNA vaccines. Looking at the vaccine approach as a whole, it should be noted that the vaccines business is generally a little less attractive than monoclonal antibodies are. That's worth pointing out. mRNA is a business we support. Our single-use products are used in mRNA. The mRNA process is very, very different, where things get synthesized from oligos or amidites or plasmids. We're involved in the precursor substances used to create the lipospheres. mRNA is less attractive than the other vaccine technologies, but we're very much involved. Let's say live attenuated or inactivated virus vaccines are a bit more attractive than mRNA vaccines. Viral vector or recombinant DNA vaccines are the most attractive ones from a value perspective for us. We don't disclose specific customer-related data, as I think you can appreciate, but we're tracking that very clearly. If your question also relates to the other business units in diagnostics, we see upsides, for instance, Pro-K, guanidine, RNA extraction kits, lateral flow membranes.
Stefan Oschmann
executiveAs I mentioned, we're involved on the vaccine side with 45 vaccine projects and 35 testing solutions. Another key point is that a number of encouraging therapeutic antibody projects are underway. Antibody work is really surging right now, in a sense for passive immunization, and that would represent an extra technology that could prove quite valuable—something of a bridging technology, so to speak. This is an extremely intricate matrix involving, I don't know, dozens of variables, and I apologize, but I'm unable to offer you a very straightforward answer.
Marcus Kuhnert
executiveTurning to your question about Glucophage's volume share within metformin, we don't reveal share figures at the level of individual products and countries. Nor do we typically separate pricing effects from volume effects. One thing I can offer as a guide: Gluco in China generates sales of between EUR 400 million and EUR 500 million, which gives you a sense of the exposure involved. As I mentioned, we're unable to share market shares or volumes of any kind.
KC Akitala
analystThanks a lot. That really helps.
Stefan Oschmann
executiveWhat we can share with you, KC, is information about how much of the hospital market Concor and Glucophage hold — for both of those assets, it's roughly 70%. That covers urban hospitals, health centers, and rural hospitals as well. There's a chance in round two to correct how our price is understood, and for Concor that's a high single-digit percentage.
KC Akitala
analystI appreciate that, both of you.
Operator
operatorThanks. Our next question is from Simon Baker at Redburn. You have the floor.
Simon Baker
analystThanks for taking my questions. If I could start with one more about Glucophage in China. Marcus, I just want to clarify what you said regarding the sales exposure of EUR 400 million-EUR 500 million. Am I right in assuming that applies to Glucophage by itself? Concor wasn't part of that. That compares with the number you cited in the 2018 annual report, EUR 329 million. Either market growth has slowed down a lot, or the current figure sits nearer the bottom of that EUR 400 million-EUR 500 million range, I'd guess. Would that be a fair assumption? And then second, slide 19, on how sales for Life Science evolved month by month, was both fascinating and really helpful. If you did a similar slide for Performance Materials, what would it look like? Thanks very much.
Marcus Kuhnert
executiveSimon, let me begin by briefly addressing your first question. I’m not certain where that figure in the 300s comes from. Glucophage sales in 2019 came to roughly EUR 400 million, and during 2020 we will grow further. That gets you to the number I just cited. It excludes Concor — it covers Glucophage only.
Stefan Oschmann
executiveSimon, regarding Performance Materials, I’d like to make one point. Right now, semiconductors account for roughly 60% of our Performance Materials business. As you’re aware, we’ve transformed this business, and we told you that semicon trends are either unaffected or boosted by the COVID crisis. If we look at Surface Solutions, overall Surface Solutions represents 2% of Merck’s revenue. If you factor in respective margins, it’s less than that on profitability. I think we shouldn’t spend too much time on that. You’re familiar with the trends in the automotive industry and in the cosmetics industry. We would not see such an uptick as we’ve seen in the other businesses for Surface Solutions. Also, coming back to the semiconductor market, we currently see massive scale-up when it comes to making PCs and making servers. On the other hand, mobile devices, there’s a certain slowdown because this is much more consumer-driven. Again, you need to factor in all these things. When it comes to display solutions, there are trends that you’re familiar with that we have communicated about. Again, we must memorize there were x10 years ago where I guess 50% of Merck’s cash flow depended on liquid crystal. Today, liquid crystal sales is 6% of Merck’s total revenue.
Stefan Oschmann
executiveI'd ask that you not read too much into this. We're observing those longer-term patterns—production moving out of Korea into China, where prices are cheaper and our market share is smaller—and we had already expected that. Beyond that, there are some consumer-side effects at play; take television sales, for example: purchases of big-screen TVs are heavily tied to major sporting occasions such as the Olympics, World Cup finals, and so on, and a lot of those have now been called off. Demand for large TVs looks weak. Let me stress once more that the key factor is the strength in semicon. There, whether we examine what our customers are telling us, look at how our competitors are doing, consider the wafer fab equipment manufacturers, or review what the industry bellwethers are forecasting, every one of those signals points upward.
Simon Baker
analystThank you very much. And just to add a quick follow-up there, Marcus: that 329 figure comes from page 214 of the 2018 annual report.
Marcus Kuhnert
executiveAll right, 2018 — that was 2 years back. In the meantime, we’ve been expanding at a strong pace, right?
Simon Baker
analystAll right, thank you very much.
Marcus Kuhnert
executiveI appreciate that.
Operator
operatorThanks. Our following question is from Daniel Wendorff at Commerzbank. Go ahead, please.
Daniel Wendorff
analystGood afternoon, gentlemen, and thank you for taking my questions. I have one follow-up regarding Life Science. Thanks once more for slides 18 and 19. Could you perhaps also share, as an exception, what organic growth Life Science saw in June? My guess would be well above 10%. A comment on that would be helpful. My second question concerns the tighter cost management you referenced in your presentation. Could you possibly quantify the savings you achieved because of COVID-19? And how sustainable do you consider them, if I think about travel expenses and perhaps new digital applications? Thank you.
Stefan Oschmann
executiveYeah, your question is sort of about monthly growth. We wanted to share some information with you on that. We don't want to change our policy of not reporting or forecasting monthly growth numbers. I hope you understand that. We don't want to go beyond what we've disclosed in these two slides. We thought it was really important for you to be able to understand the optimism we're displaying. I don't want to go into more detail about this. Marcus, on cost?
Marcus Kuhnert
executiveYes. If you examine how costs have moved in the context of COVID-19, a few separate factors are actually in play. For one thing, we obviously spend less on travel, entertainment, conferences, events, and so forth, and during the lockdown those activities have more or less stopped entirely. At the same time, freight and logistics expenses have risen. Beyond that, we also bear some additional costs tied to mask disinfection and testing — that is, for our active contribution to the fight against COVID-19. For the full year 2020, the estimated net benefit is moderate. My best guess would put it somewhere in the EUR mid double-digit million. How much of that can be sustained is hard to say, and it will depend heavily on, let's say, the new behavior once the crisis has eased, when it comes to holding events, when it comes to traveling, and so on. You can be sure that our emphasis on costs stays very strong across the whole company and has risen even further amid the current crisis.
Daniel Wendorff
analystThat’s reasonable. Thanks so much.
Operator
operatorThanks. Our next question is from Wimal Kapadia at Bernstein. Go ahead.
Wimal Kapadia
analystThank you so much for the question. This is Wimal Kapadia from Bernstein. I want to build on what you just said regarding the semiconductor market — obviously a notably robust 2Q. I suppose I was hoping for a little additional detail about how durable that pace of expansion really is. In 2H, ought we to anticipate growth decelerating, or could there be room for even more acceleration, considering that between 1Q and 2Q we observed a fairly sizable step-up in the year-on-year growth rate? And second, connected to that, which parts of the supply chain show the strongest semiconductor demand? My next question concerns MAVENCLAD. Can you provide a little more background on the source of your patient revenues during June? Did those come from newly started MAVENCLAD patients, or from existing customers entering year two of the drug? A rough breakdown along those lines would be very useful. One last quick item on display and OLED. In 2Q, was this a growing franchise — OLED especially? If it wasn't, did you in fact observe growth returning in June? Regarding margins for that business, would it be reasonable to conclude that it is now meaningfully accretive to the subdivision and to PM at a wider level?
Wimal Kapadia
analystThank you.
Stefan Oschmann
executiveI'll begin with your semiconductor question. Broadly speaking, if you look at the industry forecasts, for the full year they've recently been raised to reflect the semiconductor industry's COVID-19 resilience, let's say — which it demonstrated during the first half of 2020 — and a possible decoupling from GDP across 2020 as a whole. Allow me to repeat that. I mean, most of us spend our working days in front of laptops on Zoom or Microsoft Teams or BlueJeans or whatever. These days Taiwan is churning out laptops and PCs like crazy. Servers — there are enormous orders for servers. That's a very powerful trend in this regard. Conversely, there's softness in handheld. We're seeing softness in handheld devices, and that also explains the OLED numbers. The big turnaround in OLED hasn't shown up yet. We see no reason why it shouldn't return to the levels we were accustomed to. Unfortunately, let's say, I can't provide you with a MAVENCLAD patient split. I can't give you precise numbers. Let me try to give you a sense of it. Regarding new patient uptake, we've seen a robust rebound as of May across all major markets, including the U.S., driven mainly by the reactivation of our pre-COVID prescriber base.
Stefan Oschmann
executiveJune saw double the number of new patients that May did. And while we're on the subject, let me point out that second-year returners show a comparable pattern. Because of local treatment guidelines and how important it is to retreat patients at the appropriate time, within that second year, their uptake actually began sooner than the new patient uptake did. Marcus?
Marcus Kuhnert
executiveOkay. So, regarding your two questions about OLED. Your first one was about growth in June. Was it positive? No, not at this point. As we mentioned earlier in the presentation, we clearly expect that the present softness in OLED is only temporary. When it comes to margin, I can confirm that OLED, under normal conditions, is indeed accretive to Performance Materials. That isn't necessarily the case yet for Display, since liquid crystal remains a highly profitable business.
Wimal Kapadia
analystThanks a lot.
Operator
operatorWe’ll now take the next question from Falko Friedrich at Deutsche Bank. Please go ahead.
Falko Friedrich
analystThanks. I’ve got two questions remaining, if I may. First, how is the Versum integration coming along, and what’s driving the synergies to come in higher than your original expectation? Second, you brought up capacity expansion that’s needed in Process Solutions. Are those sizable investments that might alter your CapEx outlook either this year or next year, or is that not something to worry about?
Marcus Kuhnert
executiveAlright, Falko, let me take your first question. The Versum integration is genuinely progressing very nicely. You can see that in the outstanding business results — we already had a strong first quarter with double-digit growth on a pro forma basis. Pro forma, of course, means we report it under the portfolio effect. Strip that out and it was still double-digit, and the second quarter came in double-digit once more. On the cultural side, on the commercial side, and in doing a great deal of work while not upsetting the growth momentum in how we relate to customers, I believe we are performing very well. We are also delivering on cost synergies. To be clear, that EUR 5 million upgrade is not intended to raise the overall synergy target. We remain committed to EUR 75 million in total cost synergies. That said, we are somewhat ahead of plan on execution, and there is more to come at the Capital Markets Day.
Stefan Oschmann
executiveRegarding capacity expansion in Life Science, it’s worth pointing out, as I mentioned earlier, that this mainly involves single-use and filters. The true difficulty with adding capacity isn’t whether CapEx is available. This isn’t especially CapEx intensive. What matters more is getting it accomplished as quickly as we can. We’ve already identified buildings. As I told you, we expect this to be operational early in 2021. We believe this will return value within a very short period of time. It will not affect our 2020 CapEx guidance that we gave of EUR 1.1 billion-EUR 1.2 billion.
Falko Friedrich
analystAlright, thank you so much.
Operator
operatorMuch appreciated. Our final question today is from David Evans of Kepler Cheuvreux. The floor is yours.
David Evans
analystI really appreciate you taking my questions. I have a few focused on Process Solutions and the sharp increase in demand you're experiencing. First, I'd like to verify: are you actually declining business from any customers, or are you still holding market share across all of these segments where demand is so high? Do you expect that could shift down the road, perhaps before the additional capacity from these new investments becomes available? And would you say you're somewhat more optimistic at this point about your ability to capture at least the bulk of that added demand? Second, regarding the source of this COVID-related demand, can you roughly break it down or rank it—how much stems from vaccine-related projects, how much from therapeutics, and how much from diagnostics? Looking ahead, might any one of those segments turn out to be meaningfully larger than the others? Thank you very much.
Stefan Oschmann
executiveRegarding capacity, as I mentioned before, we're putting a lot of effort into this, and we believe we have enough available capacity over the midterm. In the current crisis situation, I think every Life Science tool company is going to need to prioritize orders. There are some smaller sub-segment products where we could sell 10x more if we were only able to produce it. I think all of our competitors face the same circumstances. We don't believe, though, that this represents a significant constraint on our growth as we move forward. As for more granularity across different segments, I think you understand that we have, how should I put it? We want to give you forecasts that are reliable, and there is so much volatility among these different sectors at present that providing that kind of detail doesn't make any sense to me.
Constantin Fest
executiveThat seems to have been the final question. So with that, Stefan, I’d like to hand things back to you for the closing remarks.
Stefan Oschmann
executiveThank you, Constantin. And thank you, everyone, for joining the call and for the ongoing interest you show in our company, in Merck. I'd like to take this chance to express appreciation to our teams across the globe. The work they're doing is fantastic. Their commitment and sense of purpose have been outstanding. I've spent a long time in this industry. Never before have I witnessed a stretch like this one, with such remarkable dedication and solidarity. Throughout it, our priorities stay clear. They are the health and safety of our employees and their families, business continuity, and continued recovery, along with our dedication to public health and to broader society. We take great pride in what we've accomplished, and we are resolved to keep moving forward, and we look forward to bringing you another update before long. With that in mind, let me note that our first virtual Capital Markets Day will take place on September 16, and we hope to — how should we put it — e-meet as many of you as possible there. Thanks once more, and goodbye.
Operator
operatorThank you all for joining us, ladies and gentlemen. That brings our call to a close. You’re welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.